Abstract: The present technology is directed generally to devices, systems, and methods for enclosing anatomical openings. In one example, an aneurysm device is endovascularly deliverable to a site proximate to an arterial aneurysm. The aneurysm device can include a closure structure having a distal-facing aspect configured to at least partially occlude the aneurysm and a proximal-facing aspect configured to arch over lumina of an artery. The closure structure can include a plurality of struts forming support arms and anchoring arms. The device further includes a supplemental stabilizer connected to the closure structure and configured to reside in the artery and press outward against a luminal wall thereof. A barrier can span at least a portion of the distal-facing aspect of the closure structure and be configured to further occlude a neck of the aneurysm. The closure structure can be configured to restrict and/or divert flow to or from the aneurysm.

Abstract: The present technology is directed generally to devices, systems, and methods for enclosing anatomical openings. In one example, an aneurysm device is endovascularly deliverable to a site proximate to an arterial aneurysm. The aneurysm device can include a closure structure having a distal-facing aspect configured to at least partially occlude the aneurysm and a proximal-facing aspect configured to arch over lumina of an artery. The closure structure can include a plurality of struts forming support arms and anchoring arms. The device further includes a supplemental stabilizer connected to the closure structure and configured to reside in the artery and press outward against a luminal wall thereof. A barrier can span at least a portion of the distal-facing aspect of the closure structure and be configured to further occlude a neck of the aneurysm. The closure structure can be configured to restrict and/or divert flow to or from the aneurysm.

Abstract: The present technology is directed generally to devices, systems, and methods for enclosing anatomical openings. In one example, an aneurysm device is endovascularly deliverable to a site proximate to an arterial aneurysm. The aneurysm device comprises a closure structure having a distal-facing aspect configured to at least partially occlude the aneurysm and a proximal-facing aspect configured to arch over lumina of an artery. The closure structure can include a plurality of struts forming support arms and anchoring arms. The device further includes a supplemental stabilizer connected to the closure structure and configured to reside in the artery and press outward against a luminal wall thereof. A barrier can span at least a portion of the distal-facing aspect of the closure structure and be configured to further occlude a neck of the aneurysm. The closure structure can be configured to restrict and/or divert flow to or from the aneurysm.

Abstract: The present technology is directed generally to devices, systems, and methods for enclosing anatomical openings. In several embodiments, an aneurysm device is endovascularly deliverable to a site proximate to an arterial aneurysm. The aneurysm device includes a closure structure having a distal-facing aspect configured to at least partially occlude the aneurysm and a proximal-facing aspect configured to arch over lumina of an artery. The device further includes a supplemental stabilizer connected to the closure structure and configured to reside in the artery and press outward against a luminal wall thereof. In some embodiments, the device can also include a barrier spanning at least a portion of the distal-facing aspect of the closure structure and configured to further occlude a neck of the aneurysm. In further embodiments, the closure structure can be configured to restrict and/or divert flow to or from the aneurysm.

Abstract: The present technology is directed generally to devices, systems, and methods for enclosing anatomical openings. In several embodiments, an aneurysm device is endovascularly deliverable to a site proximate to an arterial aneurysm. The aneurysm device includes a closure structure having a distal-facing aspect configured to at least partially occlude the aneurysm and a proximal-facing aspect configured to arch over lumina of an artery. The device further includes a supplemental stabilizer connected to the closure structure and configured to reside in the artery and press outward against a luminal wall thereof. In some embodiments, the device can also include a barrier spanning at least a portion of the distal-facing aspect of the closure structure and configured to further occlude a neck of the aneurysm. In further embodiments, the closure structure can be configured to restrict and/or divert flow to or from the aneurysm.

Abstract: The present technology is directed generally to devices, systems, and methods for enclosing anatomical openings. In several embodiments, an aneurysm device is endovascularly deliverable to a site proximate to an arterial aneurysm. The aneurysm device includes a closure structure having a distal-facing aspect configured to at least partially occlude the aneurysm and a proximal-facing aspect configured to arch over lumina of an artery. The device further includes a supplemental stabilizer connected to the closure structure and configured to reside in the artery and press outward against a luminal wall thereof. In some embodiments, the device can also include a barrier spanning at least a portion of the distal-facing aspect of the closure structure and configured to further occlude a neck of the aneurysm. In further embodiments, the closure structure can be configured to restrict and/or divert flow to or from the aneurysm.

Abstract: The present technology is directed generally to devices, systems, and methods for enclosing anatomical openings. In several embodiments, an aneurysm device is endovascularly deliverable to a site proximate to an arterial aneurysm. The aneurysm device comprises a closure structure having a distal-facing aspect configured to at least partially occlude the aneurysm and a proximal-facing aspect configured to arch over lumina of an artery. The device further includes a supplemental stabilizer connected to the closure structure and configured to reside in the artery and press outward against a luminal wall thereof. In some embodiments, the device can also include a barrier spanning at least a portion of the distal-facing aspect of the closure structure and configured to further occlude a neck of the aneurysm. In further embodiments, the closure structure can be configured to restrict and/or divert flow to or from the aneurysm.

Abstract: The present technology is directed generally to devices, systems, and methods for enclosing anatomical openings. In several embodiments, an aneurysm device is endovascularly deliverable to a site proximate to an arterial aneurysm. The aneurysm device includes a closure structure having a distal-facing aspect configured to at least partially occlude the aneurysm and a proximal-facing aspect configured to arch over lumina of an artery. The device further includes a supplemental stabilizer connected to the closure structure and configured to reside in the artery and press outward against a luminal wall thereof. In some embodiments, the device can also include a barrier spanning at least a portion of the distal-facing aspect of the closure structure and configured to further occlude a neck of the aneurysm. In further embodiments, the closure structure can be configured to restrict and/or divert flow to or from the aneurysm.

Abstract: The present invention is directed to methods for providing long-term treatment of fibromyalgia syndrome (FMS) by administering a dual re-uptake inhibitor to a patient with FMS. More particularly, the present invention is directed to the long-term treatment of FMS by administering a norepinephrine-serotonin reuptake inhibitor (NSRI) to a patient with FMS.

Abstract: The present invention provides methods of diagnosing and monitoring systemic lupus erythematosus by measuring cell-based complement activation products (CB-CAPS) in a subject's blood. In particular, the invention describes a diagnostic method employing the measurement of multiple complement activation products on the surfaces of red blood cells, white blood cells, and platelets (e.g., EC4d, BC4d, PC4d, and ECR1). A diagnostic algorithm utilizing the determined levels of CB-CAPS is also disclosed.

Abstract: Methods for improving physical function in fibromyalgia syndrome by administering an NSRI such as milnacipran as disclosed.

Abstract: The present invention is directed to methods for providing long-term treatment of fibromyalgia syndrome (FMS) by administering a dual re-uptake inhibitor to a patient with FMS. More particularly, the present invention is directed to the long-term treatment of FMS by administering a norepinephrine-serotonin reuptake inhibitor (NSRI) to a patient with FMS.